Prevalence and clinical correlations of somatostatin receptor-2 (SSTR2) expression in neuroblastoma

Natasha Alexander, Paula Marrano, Paul Thorner, Arlene Naranjo, Collin Van Ryn, Daniel Martinez, Vandana Batra, Libo Zhang, Meredith S. Irwin, Sylvain Baruchel

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Alternative radiolabeled, targeted agents are being investigated for children with relapsed neuroblastoma (NB) who do not respond to I131-metaiodobenzylguanidine (MIBG) therapy. (DOTA0-Tyr3)-octreotate targets somatostatin receptors (SSTRs), particularly SSTR2, which are expressed on NB cells. We investigated SSTR2 expression in NB tumors (36 high-risk [HR]; 33 non- HR patients) and correlated SSTR2 levels with clinical features, norepinephrine transporter (NET) expression, and MIBG avidity. SSTR2 and NET immunohistochemistry scores (0 to 3) were calculated on biopsies using digital image analysis based on staining intensity and distribution. Clinical data were correlated with SSTR2 expression. Median SSTR2 score for 69 patients was 1.31 (0.26 to 2.55). Non-HR NB was associated with a higher SSTR2 score (P=0.032). The SSTR2 expression did not correlate with age, International Neuroblastoma Staging System (INSS) stage, MYCN amplification and histology. Higher SSTR2 scores were observed in MIBG-avid versus MIBG-nonavid NB. SSTR2 score was not significantly associated with NET score (r=-0.062, P=0.62). Twenty-six patients who relapsed or progressed had a median SSTR2 score of 1.33 (0.26 to 2.55). Patients with NB including relapsed or progressive disease showed SSTR2 expression at diagnosis, suggesting they could be candidates for radiolabeled-DOTA-conjugated peptide imaging or therapy.

Original languageEnglish (US)
Pages (from-to)222-227
Number of pages6
JournalJournal of pediatric hematology/oncology
Volume41
Issue number3
DOIs
StatePublished - Apr 1 2019
Externally publishedYes

Bibliographical note

Funding Information:
This study was funded by the James Birrell Fund for Neuroblastoma Research and Curtis Chow Memorial Fund. NA was funded by a fellowship from the Sick Kids Garron Family Cancer Center as the UA Local 46 Childhood Cancer Fellow. AN and CV were funded by NIH/NCI grant U10 CA180899 for the Children's Oncology Group Statistics and Data Center.

Funding Information:
This study was funded by the James Birrell Fund for Neuroblastoma Research and Curtis Chow Memorial Fund. NA was funded by a fellowship from the Sick Kids Garron Family Cancer Center as the UA Local 46 Childhood Cancer Fellow. AN and CV were funded by NIH/NCI grant U10 CA180899 for the Children’s Oncology Group Statistics and Data Center.

Publisher Copyright:
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

Keywords

  • Neuroblastoma
  • Norepinephrine transporter
  • SSTR2
  • Somatostatin receptor-2

Fingerprint Dive into the research topics of 'Prevalence and clinical correlations of somatostatin receptor-2 (SSTR2) expression in neuroblastoma'. Together they form a unique fingerprint.

Cite this